Welcome to our dedicated page for Blade Air Mobility SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to decode Blade Air Mobility’s blend of life-saving organ transport and passenger helicopter routes? Start here. Our platform walks you through every SEC disclosure, from the first 8-K on a new hospital contract to the footnotes about Electric Vertical Aircraft in the annual report.
Use the search bar or follow the quick links below to jump directly to a Blade Air Mobility quarterly earnings report 10-Q filing or skim the Blade Air Mobility annual report 10-K simplified. Each document arrives within seconds of hitting EDGAR, accompanied by AI-powered summaries that highlight Medical-segment margins, passenger load factors, and fleet-transition costs—no accounting background required.
- Need real-time alerts? Track Blade Air Mobility Form 4 insider transactions real-time and spot buying or selling trends among directors.
- Review governance details in the Blade Air Mobility proxy statement executive compensation without wading through tables.
- Stay on top of Blade Air Mobility 8-K material events explained—from new transplant-center partnerships to aircraft supplier updates.
Common questions like “Blade Air Mobility insider trading Form 4 transactions” or “understanding Blade Air Mobility SEC documents with AI” are answered directly inside each filing card. Our AI pinpoints the revenue mix for every quarter, flags unusual related-party deals, and compares pay packages—all while keeping the full text a click away.
Whether you’re seeking a concise Blade Air Mobility earnings report filing analysis or verifying Blade Air Mobility executive stock transactions Form 4, our coverage ensures you won’t miss a detail. Complex aviation logistics just became readable.
Strata Critical Medical, Inc. director and Co-CEO/General Counsel Melissa M. Tomkiel reported a routine equity-related transaction. On 12/10/2025, 34,018 shares of Class A common stock were disposed of at $4.38 per share under transaction code F.
After this transaction, she beneficially owned 1,366,402 Class A shares, held directly. A footnote explains that the shares were withheld by the issuer to satisfy tax withholding obligations arising from the vesting of restricted stock units, rather than being sold in the open market.
Strata Critical Medical, Inc. reported an insider equity transaction by director and Co‑CEO and CFO William A. Heyburn on 12/10/2025. The filing shows 35,348 shares of Class A common stock were withheld by the company at $4.38 per share to cover tax obligations tied to vesting restricted stock units. After this tax withholding, he directly beneficially owned 1,368,088 shares of Class A common stock.
Strata Critical Medical, Inc. reported an insider transaction by an officer who serves as CEO of Trinity Air Medical. On 12/10/2025, the officer had 21,643 shares of Class A common stock withheld at $4.38 per share, recorded under transaction code F, in connection with tax withholding on vesting restricted stock units.
After this transaction, the officer beneficially owned 293,395 shares directly and 382,987 shares indirectly through a limited liability company of which the officer is the sole member. The filing describes the transaction as issuer share withholding to satisfy tax obligations related to equity compensation.
Strata Critical Medical, Inc. reported an insider tax-withholding transaction involving 3,716 shares of its Class A common stock. On 12/10/2025, Chief Accounting Officer Amir Cohen had 3,716 shares withheld at $4.38 per share to satisfy tax obligations triggered by the vesting of restricted stock units, and he now beneficially owns 117,626 shares directly.
Strata Critical Medical, Inc. (SRTA)11/20/2025, the director sold 11,000 shares of Class A common stock at a price of $4.37 per share, coded as an open-market sale (transaction code S). After this transaction, the director beneficially owns 113,897 shares directly. The filing is a single‑reporting‑person Form 4 and does not list any derivative securities activity.
Strata Critical Medical, Inc. filed a Form S-8 to register 12,104,544 shares of common stock for issuance under its 2021 Omnibus Incentive Plan. These shares support equity compensation for employees, directors and other service providers and are in addition to amounts previously registered under earlier Form S-8 filings. The newly registered pool includes shares added through the plan’s annual “evergreen” increase, shares recycled from expired or forfeited awards under a prior Fly Blade, Inc. plan, and shares from awards under the current plan that expired or were settled without stock issuance. The company incorporates by reference its recent 10-K, 10-Qs and 8-Ks and lists standard exhibits such as its charter, bylaws, the incentive plan and legal opinions.
Strata Critical Medical, Inc. reported an insider transaction by a director on a Form 4. On 11/19/2025, the reporting person sold 11,000 shares of Class A common stock at a weighted average price of $4.3122 per share, with individual trade prices ranging from $4.31 to $4.32. After this sale, the director beneficially owns 124,897 shares of the company’s Class A common stock, held directly. No derivative securities transactions were reported in this filing.
Strata Critical Medical (SRTA): Co-CEO, General Counsel, and Director Melissa M. Tomkiel exercised employee stock options and acquired 27,778 shares of Class A common stock at $0.18 per share on 11/07/2025 (transaction code M). Following the transaction, she beneficially owns 1,400,420 shares, held directly.
The exercised options relate to grants first exercisable on 05/07/2021 and expiring on 07/28/2030. After this activity, 276,960 stock options remain beneficially owned, held directly.
Strata Critical Medical (formerly Blade) reported Q3 2025 results highlighting a strategic pivot to healthcare services. Revenue from continuing operations reached $49,298 (vs. $36,062 a year ago), while operating loss narrowed to $5,622. The quarter’s net income of $57,416 was driven by discontinued operations following the Passenger business sale.
On August 29, Strata sold its Passenger business to a Joby Aviation subsidiary for consideration valued at $75,357 in Joby shares and later sold those shares for net proceeds of $70,163. The company may receive up to an additional $35,000 based on performance and retention targets, plus up to $10,000 in indemnity holdbacks. On September 16, Strata acquired Keystone Perfusion Services for $109,963 in cash and 3,434,609 shares valued at $16,828, adding $69,067 of goodwill and $42,600 of identifiable intangibles.
Cash and cash equivalents were $22,753 and short‑term investments were $53,165 as of September 30, 2025. Basic and diluted EPS were $0.70, reflecting a continuing operations loss of $0.12 and discontinued operations income of $0.81. Shares outstanding were 86,366,526 as of November 3, 2025.
Strata Critical Medical, Inc. furnished a Form 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The disclosure is provided under Item 2.02, Results of Operations and Financial Condition, and is designated as furnished, not filed, under the Exchange Act.
FAQ
What is the current stock price of Blade Air Mobility (BLDE)?
What is the market cap of Blade Air Mobility (BLDE)?
